Research Paper Volume 8, Issue 12 pp 3298—3310

Figure 1. miR-34a expression is significantly increased in both HIV-infected, and antiretroviral agents, ritonavir and lopinavir-treated human and mouse vessels and vascular ECs both in vitro and in vivo. miR-34a expression in arterial vessels (A) and in ECs isolated from these vessels (B) in HIV-infected patients with and without antiretroviral therapy (lopinavir/ritonavir, 800/200mg daily dose) and in their controls. miR-34a expression arterial vessels (C) and in ECs isolated from these vessels (D) in HIV-1 Tat transgenic mice and in mice with antiretroviral therapy (lopinavir/ritonavir, 125/31.25 mg/kg daily dose), as well as their controls. The effects of Tat1-101 (E), ritonavir or lopinavir plus ritonavir (lopinavir/ritonavir) (F) on the expression of miR-34a in human and mouse ECs. Note: n=6-9; *p<0.05 compared with the groups from HIV patients without antiretroviral therapy in (A) and (B), with the groups from wild-type mice or vehicle treated mice in (C) and (D), and with vehicle-treated groups in (E) and (F).